Ashley Yeo is attached to the medtech titles within Informa’s Pharma intelligence division.
As Health Care editor on In Vivo (monthly hardcopy and online daily services), he writes and commissions news and feature material to meet the strategic business and market access information needs of senior players and device makers as they move innovations into the global medtech market place.
As part of the Principal Analyst team, he also contributes news delivery and insight needs across the group’s other medtech titles in the field of market access (global regulatory, reimbursement, policy changes). Key areas of focus are Germany, the UK and global themes, and EU and other outside global regulatory insight.
A linguist by training, he joined what was later to become Informa in mid-1988 as a French and German news reporter (with some other European languages also in the mix), and has been editor of three of the group’s titles (including Clinica) over a 14-year-period.
These duties are combined with supporting the growing Ask The Analyst service. He says: “This helps us as a group keep a close relationship with long-term and potential subscribers in a sector where insight and knowledge are key to our clients’ commercial success.”
Latest From Ashley Yeo
The much-anticipated return to a “normal” NHS service delivery could yet be dashed by a resurgence of the virus.
Hospital administrators and clinicians in Germany seek enhanced digitization of clinical procedures, but the budgets have not always been available. A new “future hospitals investment” program, now made into a draft law, should reserve funds for robotics and digital health care.
In this Device Week, Ashley Yeo asks PB Consulting managing director Dan Jones about the adjustments needed by UK medtechs as they face a confluence of change brought about by Brexit, COVID-19 and NHS reform, at a time when the MHRA is also coming under increased scrutiny.
Entrepreneur Carlo Rivis, one of In Vivo’s Rising Leaders, brought his disruptive innovation approaches to in-silico trials and digital avatar developer Computational Life, and now he is doing the same at Innovation Discovery.
COVID-19 is of no lesser importance to the UK medtech industry, but attention is now refocusing on Brexit, future regulation and trade deals.
Better medtech industry-government dialog is needed to improve the adoption of innovative medical devices by the French health care system. The current pathway is not obvious or easy, according to local manufacturers.